Activities Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th June 2020 and a Q2 2020 sales…
Read moreNews & Views
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion…
Read more
Telix Receives FDA Feedback on Phase 3 Trial Design for Prostate Cancer Therapy Product
Telix Pharmaceuticals Limited announces that the FDA has provided feedback that will enable the Company to finalize the Phase 3 PROSTACT…
Read more
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal cancer imaging product…
Read more
Recommencement of ZIRCON Phase III Trial Recruitment in EU
Telix Pharmaceuticals Limited announces that the Company’s ZIRCON phase III trial of TLX250-CDx has recommenced patient recruitment in…
Read more
Presentation to Jefferies Virtual Healthcare Conference
Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare…
Read more
Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer
News,
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer…
Read more
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29…
Read more
Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings…
Read more